131 results
Page 2 of 7
8-K
EX-99.1
w3zyiqdff6y2q
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-3.1
nax9gwx
18 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
EX-99.1
kycqreymlimp1r
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
c0d3fd wff
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
dn1cj t9zsso0
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
ki1zf1 8y
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
p88pxz3
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.2
y3njjbr
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
p4t00 fyp21roy8zaf45
24 May 22
Submission of Matters to a Vote of Security Holders
5:01pm
DFAN14A
c0odvj
16 May 22
Additional proxy materials by non-management
2:04pm
DFAN14A
EX-99.1
5a9yawng0ta4 oygo
16 May 22
Additional proxy materials by non-management
2:04pm
8-K
EX-99.1
k8502oucw
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DFAN14A
lacad48si66 nea
12 May 22
Additional proxy materials by non-management
2:06pm
DFAN14A
EX-99.1
6jusj00zu9yd9w
12 May 22
Additional proxy materials by non-management
2:06pm
DEFA14A
c7zxyzjf1
11 May 22
Additional proxy soliciting materials
4:49pm